Opexa Therapeutics, Inc. (NASDAQ: OPXA)

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company, has focused their efforts on the development of patient-specific cellular therapies designed to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. Tovaxin, the company’s lead product candidate, is an innovative T-cell vaccine used to treat MS. Results from the Phase IIb study have shown a positive trend in reducing annualized relapse rate for patients treated with the drug compared to placebo. For further information, visit the Company’s web site at www.opexatherapeutics.com.